Fundraising Overview - The company has been approved to issue up to 33,201,000 new shares, ultimately issuing 21,405,636 shares at a price of RMB 28.03 per share, raising a total of RMB 599,999,977.08, with a net amount of RMB 589,055,124.31 after deducting related expenses [2][4][6] Fund Management - The company has established a fundraising management system to ensure the proper use of raised funds, implementing strict approval processes and dedicated account management [2][6] - A tripartite supervision agreement was signed with banks to oversee the management of the raised funds [3][4] Project Updates - In August 2023, the company approved changes to the implementation subject, location, investment structure, and funding method for the "Destination Charging Station Construction Project" [4][5] - By December 2023, the remaining funds were transferred to a dedicated account for the new implementation subject, Shanghai Qunying Junyue Energy Technology Co., Ltd. [5][6] Project Termination - In December 2024, the company concluded the "Destination Charging Station Construction Project" and terminated the "New Energy Vehicle Charging Equipment and Operation Platform Development Project," reallocating the remaining funds to supplement working capital [6][7] - The company completed all payments for contracts related to the terminated project and has since closed the corresponding fundraising accounts [7][8]

Core Viewpoint - The company has decided to terminate part of its fundraising projects and delay others, based on a careful assessment of the current market conditions and project progress, ensuring that these decisions align with the long-term interests of the company and its shareholders [1][10]. Fundraising Overview - The company raised a net amount of RMB 1,002,572,682.71 through its initial public offering, verified by an accounting firm [1]. - The company has established a management system for the use of raised funds, ensuring that funds are stored in dedicated accounts and used strictly for their intended purposes [2]. Termination of Fundraising Projects - The project "Zihang Medical Device Component Intelligent Manufacturing and Expansion Project" will be terminated, with the total investment amount reduced from RMB 282.84 million to RMB 143.47 million, and the fundraising investment amount decreased from RMB 282.84 million to RMB 135.77 million [3]. - The termination is influenced by changes in market demand and increased competition, leading to a reassessment of the project's viability [6][7]. Reasons for Project Termination - The implementation of centralized procurement policies has created volatility in market demand, affecting the sales cycle and capacity planning for the project [6]. - The existing production capacity is deemed sufficient to meet current demand, and further investment could lead to idle capacity risks [7]. Impact of Project Termination - The termination is expected to enhance the efficiency of fundraising usage and will not adversely affect the company's normal operations or shareholder interests [8]. - The remaining funds from the terminated project will be retained in dedicated accounts for future investment opportunities [8]. Delay of Fundraising Projects - The "Weike Medical Minimally Invasive Surgical New Product Project" will be delayed, with the expected completion date pushed from June 30, 2025, to December 31, 2027 [9]. - The delay is attributed to changes in market conditions and the need for further product development to meet diverse customer needs [9]. Reasons for Project Delay - The company is adapting to market changes and enhancing product features through increased R&D investment, which has necessitated a phased approach to project implementation [9]. - The execution of procurement policies has affected the expected market release timeline for the company's products [9]. Impact of Project Delay - The delay is a strategic decision that does not involve changes to the project’s implementation structure or total investment, ensuring that it aligns with the company's long-term development goals [9][10].

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].

Core Viewpoint - The termination of three fundraising projects by Zhihua Technology raises questions about the company's operational decisions and financial management, especially given the significant losses reported in recent years [2][4][8]. Group 1: Fundraising and Project Termination - On May 12, Zhihua Technology announced the termination of three fundraising projects, reallocating the remaining 329 million yuan to supplement working capital permanently [2][4]. - The three projects were part of a 1.079 billion yuan fundraising effort initiated in late 2020, with approximately 174 million yuan already invested over four years [2][4][5]. - The terminated projects include the construction of production bases in Vietnam for electronic components and heat dissipation components, with investment progress at 46.78%, 25.26%, and 30.12% respectively [5][6]. Group 2: Financial Performance - Zhihua Technology has faced operational challenges, reporting a cumulative net loss of 628 million yuan from 2022 to 2024, with continued losses in the first quarter of this year [2][9]. - The company has not distributed cash dividends to shareholders since 2022, reflecting its ongoing financial difficulties [3][10]. - Despite a slight revenue increase in the first quarter of this year, the company continues to struggle with low gross margins and high operational costs, leading to persistent losses [9][10]. Group 3: Market Context - The consumer electronics industry has experienced cyclical fluctuations, impacting Zhihua Technology's performance and leading to a weaker-than-expected recovery in demand [2][9]. - The company’s revenue has shown volatility, with a decline in both revenue and net profit since its IPO in 2017, highlighting ongoing challenges in achieving stable growth [8][9].

Group 1 - The company will hold a shareholders' meeting on May 20, 2025, at 14:30 in Beijing, with a registration date of May 12, 2025 [2][3] - The agenda includes reading the meeting notice, reviewing various proposals, and discussing the 2024 annual reports from the board and supervisory committee [2][4] - The company reported a net profit attributable to shareholders of -902.56 million yuan for 2024, with total assets decreasing by 16.75% to 400.80 billion yuan [5][6][9] Group 2 - The company plans to not distribute profits for the 2024 fiscal year, with retained earnings at 284.92 million yuan as of December 31, 2024 [9][10] - The company intends to appoint Beijing Dehao International Accounting Firm for the 2025 financial audit [10] - The company proposed to terminate the "Chongqing Oriental Fashion Driving Training Base Construction Project" due to prolonged non-use and financial pressures, with total investment in the project reaching 110.83 million yuan [11][22][23]

4月17日，国联水产（300094）发布公告称，公司于2025年4月17日召开第六届董事会第十一次会议及第 六届监事会第十次会议，审议通过了《关于终止部分募投项目并将募集资金永久补充流动资金的议 案》，同意公司终止募集资金投资项目"国联（益阳）食品有限公司水产品深加工扩建项目"并将相应募 集资金永久补充流动资金，本议案尚需提交公司股东大会审议。 国联（益阳）食品有限公司水产品深加工扩建项目（以下简称"水产品深加工扩建项目"），主要产品为 小龙虾和鱼类深加工产品。项目拟新建 15，000.00㎡生产厂房、7，200.00 ㎡自动化立体冷库、12， 000.00 ㎡宿舍楼、4，000.00 ㎡办公楼及其它附属建筑。项目将新购置进口节能蒸煮机、自动智能分选 机、进口智能化速冻机、进口自动化包装线设备等自动化生产设备。 来源：粤股8 项目总投资 60，171.51 万元，规划建设期 12 个月，在项目期内将完成建筑工程、设备购置安装及完善 人员配置等。项目达产后将新增年产能 1.53 万吨小龙虾和 2.97 万吨鱼类深加工产品，本项目的实施旨 在扩大公司水产品深加工的产能，满足日益增长的市场需求。 水产品深加工扩建项 ...